MedSci Healthcare (2415) H2 2025 earnings summary

Executive summary

• FY2025 revenue rose 3.74% YoY to RMB270.4m, while profit for the year fell 28.16% to RMB17.9m.

• Strategic focus shifted toward AI-enabled evidence services, precision marketing, real-world studies and international expansion.

Financial highlights

• Gross profit was RMB160.4m, down 1.07% YoY; gross margin was 59.34%, slightly below 2024.

• Other income and gains declined to RMB12.2m from RMB41.3m; selling and distribution expenses fell 23.3% to RMB60.4m, while R&D expenses rose to RMB30.7m from RMB23.2m.

• Profit before tax was RMB19.5m versus RMB25.5m; income tax expense increased to RMB1.6m from RMB0.5m.

• Basic and diluted EPS were RMB0.03 each, versus RMB0.05 each in 2024.

Outlook and guidance

• Priorities are academically driven precision services, AI-led innovation and international expansion, including deeper coordination across physician platforms, precision marketing and RWS.

• AI services have begun generating scaled revenue; further R&D investment in SeekEvidence and DeepEvidence is planned, with expectations for continued rapid growth in AI services.

• Plans include upgrading digital services to intelligent services and expanding AI across research, clinical, marketing and internal operating workflows.